Home > Press > NanoKTN announces IPO of member Ilika plc on AIM
Abstract:
Raises £5.2 million with market capitalisation of £18.7 million
The NanoKTN is pleased to announce the AIM IPO of one of its members, Ilika.
Ilika plc ("Ilika") (AIM: IKA) is an advanced cleantech materials discovery company. It accelerates the discovery of new and patentable materials using a unique high throughput technologies (HTT) process for identified end uses in the energy, electronics and biomedical sectors. This process enables hundreds of scalable materials to be made in a single, automated operation and subsequently tested for key properties.
Ilika raised £5.2 million before expenses through the issue of 10,147,059 Placing Shares at 51 pence per share. On Admission, the Company had 36,569,359 Ordinary Shares in issue and a market capitalisation of approximately £18.7 million.
The NanoKTN has supported Ilika since its origins as a spin-out company from the University of Southampton. Its first major activity with the NanoKTN was as a delegate on the Germany Nanomission 2008, a high-profile workshop and networking event held at the British Embassy in Berlin. Ilika joined other innovative nanotechnology companies in the UK to meet with German organisations to discuss the application of nanotechnology to the needs of the energy and environment sector. The mission resulted in a number of follow-on activities between Ilika and two major German manufacturers as well as a number of UK companies.
"The NanoKTN has been extremely supportive of Ilika as it has grown since its spinout from the University of Southampton in 2004. In particular, the NanoKTN has facilitated some first-class networking opportunities which have formed an important part of Ilika's business development activities," comments CEO of Ilika, Graeme Purdy. "The NanoKTN plays an important role in highlighting the commercial benefits of innovative materials science to grant bodies. This has undoubtedly reinforced Ilika's successful applications for grant funding, particularly in the area of hydrogen storage."
Director at the NanoKTN, Alec Reader, adds, "The AIM IPO of Ilika is excellent news for the nanotechnology industry. Our key aim is to support innovative companies to create wealth for the UK industry - the NanoKTN has worked intimately with Ilika from spinout to listed company and the results have been tremendous."
The NanoKTN's primary aim is to encourage collaboration and knowledge transfer between key players in industry, as well as start-ups and SMEs. One of the key methods to ensure networking between key market players is to facilitate interactions through networking and event organisation.
####
About NanoKTN
The mission of the Nanotechnology Knowledge Transfer Network (NanoKTN) is to encourage and support organisations to collaborate and share knowledge with key partners in attractive end user markets to achieve growth of the UK nanotechnology sector.
For more information, please click here
Copyright © NanoKTN
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||